S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
66,000% upside on tiny biotech? (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
66,000% upside on tiny biotech? (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
66,000% upside on tiny biotech? (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
S&P 500   4,288.05
DOW   33,507.50
QQQ   358.27
Will the Energy Sector Continue to Outshine the Market?
66,000% upside on tiny biotech? (Ad)
Borrowers are reassessing their budgets as student loan payments resume after pandemic pause
MarketBeat Week in Review – 9/25 - 9/29
66,000% upside on tiny biotech? (Ad)
Cyprus hails Moody's two-notch credit rating upgrade bringing the country into investment grade
Almost all of Nagorno-Karabakh's people have left, Armenia's government says
66,000% upside on tiny biotech? (Ad)
Powerball jackpot rises to $1.04 billion after another drawing without a big winner
Promoting tradition as well as beans, Ethiopian coffee shops find fans far from home
NASDAQ:IRIX

IRIDEX (IRIX) Stock Forecast, Price & News

$2.54
+0.47 (+22.71%)
(As of 09/29/2023 ET)
Compare
Today's Range
$2.04
$2.57
50-Day Range
$1.33
$2.54
52-Week Range
$1.31
$2.74
Volume
369,231 shs
Average Volume
69,756 shs
Market Capitalization
$41.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

IRIDEX MarketRank™ Forecast

Analyst Rating
0.00 Rating Score
Upside/​Downside
21.3% Downside
$2.00 Price Target
Short Interest
Healthy
0.78% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of IRIDEX in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.48) to ($0.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

0.74 out of 5 stars

Computer And Technology Sector

603rd out of 605 stocks

Electromedical Equipment Industry

20th out of 20 stocks


IRIX stock logo

About IRIDEX (NASDAQ:IRIX) Stock

IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. It offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser systems, which are used for the treatment of retinal disorders; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. The company also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. It offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system to perform MicroPulse transscleral laser therapy; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. The company serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, veterinary practices, and office clinics. It markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was incorporated in 1989 and is headquartered in Mountain View, California.

IRIX Price History

IRIX Stock News Headlines

IRIDEX (NASDAQ:IRIX) Earns Buy Rating from Analysts at StockNews.com
[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"
The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. Get the name of the stock here >>>
Iridex Reports Second Quarter 2023 Financial Results
IRIDEX earnings preview: what Wall Street is expecting
This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Iridex: Q1 Earnings Insights
Iridex Reports First Quarter 2023 Financial Results
Iridex to Present at the 35th Annual Roth Conference
IRIDEX Third Quarter 2022 Earnings: Beats Expectations
See More Headlines
Receive IRIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IRIDEX and its competitors with MarketBeat's FREE daily newsletter.

IRIX Company Calendar

Last Earnings
8/10/2023
Today
9/30/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Electromedical equipment
Sub-Industry
N/A
Current Symbol
NASDAQ:IRIX
Employees
130
Year Founded
1989

Price Target and Rating

Average Stock Price Forecast
$2.00
High Stock Price Forecast
$2.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
-21.3%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-7,550,000.00
Pretax Margin
-13.69%

Debt

Sales & Book Value

Annual Sales
$56.97 million
Book Value
$1.08 per share

Miscellaneous

Free Float
15,223,000
Market Cap
$41.22 million
Optionable
Not Optionable
Beta
1.19

Social Links

Investing Strategies To Help Grow Your Retirement Income Cover

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Key Executives

  • Mr. David I. Bruce (Age 64)
    Pres, CEO & Director
    Comp: $459.31k
  • Mr. Patrick Mercer (Age 51)
    Chief Operating Officer
    Comp: $385.51k
  • Ms. Leigh Salvo
    Head of Investor Relations













IRIX Stock - Frequently Asked Questions

What is IRIDEX's stock price forecast for 2023?

0 equities research analysts have issued 12-month target prices for IRIDEX's shares. Their IRIX share price forecasts range from $2.00 to $2.00. On average, they expect the company's share price to reach $2.00 in the next twelve months. This suggests that the stock has a possible downside of 21.3%.
View analysts price targets for IRIX
or view top-rated stocks among Wall Street analysts.

How have IRIX shares performed in 2023?

IRIDEX's stock was trading at $2.01 at the start of the year. Since then, IRIX shares have increased by 26.4% and is now trading at $2.54.
View the best growth stocks for 2023 here
.

Are investors shorting IRIDEX?

IRIDEX saw a increase in short interest during the month of September. As of September 15th, there was short interest totaling 93,600 shares, an increase of 52.9% from the August 31st total of 61,200 shares. Based on an average daily trading volume, of 41,600 shares, the days-to-cover ratio is currently 2.3 days. Currently, 0.8% of the company's stock are short sold.
View IRIDEX's Short Interest
.

When is IRIDEX's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our IRIX earnings forecast
.

How were IRIDEX's earnings last quarter?

IRIDEX Co. (NASDAQ:IRIX) released its earnings results on Thursday, August, 10th. The medical equipment provider reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by $0.06. The medical equipment provider had revenue of $12.86 million for the quarter, compared to analysts' expectations of $14.23 million. IRIDEX had a negative net margin of 13.78% and a negative trailing twelve-month return on equity of 48.09%.

What guidance has IRIDEX issued on next quarter's earnings?

IRIDEX issued an update on its FY 2023 earnings guidance on Thursday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $55.00 million-$57.00 million, compared to the consensus revenue estimate of $58.05 million.

What is Theodore A. Boutacoff's approval rating as IRIDEX's CEO?

7 employees have rated IRIDEX Chief Executive Officer Theodore A. Boutacoff on Glassdoor.com. Theodore A. Boutacoff has an approval rating of 64% among the company's employees.

What other stocks do shareholders of IRIDEX own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IRIDEX investors own include NVIDIA (NVDA), Trevena (TRVN), CTI BioPharma (CTIC), Agile Therapeutics (AGRX), Genocea Biosciences (GNCA), Idera Pharmaceuticals (IDRA), Lipocine (LPCN), Rigel Pharmaceuticals (RIGL) and SCYNEXIS (SCYX).

What is IRIDEX's stock symbol?

IRIDEX trades on the NASDAQ under the ticker symbol "IRIX."

How do I buy shares of IRIDEX?

Shares of IRIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IRIDEX's stock price today?

One share of IRIX stock can currently be purchased for approximately $2.54.

How much money does IRIDEX make?

IRIDEX (NASDAQ:IRIX) has a market capitalization of $41.22 million and generates $56.97 million in revenue each year. The medical equipment provider earns $-7,550,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

How many employees does IRIDEX have?

The company employs 130 workers across the globe.

How can I contact IRIDEX?

IRIDEX's mailing address is 1212 Terra Bella Avenue, Mountain View CA, 94043. The official website for the company is www.iridex.com. The medical equipment provider can be reached via phone at (650) 940-4700, via email at investors@iridex.com, or via fax at 650-940-4710.

This page (NASDAQ:IRIX) was last updated on 10/1/2023 by MarketBeat.com Staff

My Account -